153 related articles for article (PubMed ID: 34282791)
1. Neuroblastoma Molecular Risk-Stratification of DNA Copy Number and
Kahana-Edwin S; Cain LE; McCowage G; Darmanian A; Wright D; Mullins A; Saletta F; Karpelowsky J
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282791
[TBL] [Abstract][Full Text] [Related]
2. Using droplet digital PCR to analyze
Lodrini M; Sprüssel A; Astrahantseff K; Tiburtius D; Konschak R; Lode HN; Fischer M; Keilholz U; Eggert A; Deubzer HE
Oncotarget; 2017 Oct; 8(49):85234-85251. PubMed ID: 29156716
[TBL] [Abstract][Full Text] [Related]
3. Sequential analysis of cfDNA reveals clonal evolution in neuroblastoma patients receiving ALK targeted therapy.
Bobin C; Iddir Y; Butterworth C; Masliah-Planchon J; Saint-Charles A; Bellini A; Bhalshankar J; Pierron G; Combaret V; Attignon V; André N; Corradini N; Dumont B; Mansuy L; Khanfar C; Klein S; Briandet C; Plantaz D; Millot F; Thouvenin S; Aerts I; Ndounga-Diakou LA; Laghouati S; Abbou S; Jehanno N; Tissot H; Renault S; Baulande S; Raynal V; Bozec L; Bieche I; Delattre O; Berlanga P; Schleiermacher G
Clin Cancer Res; 2024 May; ():. PubMed ID: 38787533
[TBL] [Abstract][Full Text] [Related]
4. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
[TBL] [Abstract][Full Text] [Related]
5. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
6. Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma.
Lodrini M; Graef J; Thole-Kliesch TM; Astrahantseff K; Sprüssel A; Grimaldi M; Peitz C; Linke RB; Hollander JF; Lankes E; Künkele A; Oevermann L; Schwabe G; Fuchs J; Szymansky A; Schulte JH; Hundsdörfer P; Eckert C; Amthauer H; Eggert A; Deubzer HE
Clin Cancer Res; 2022 May; 28(9):1809-1820. PubMed ID: 35247920
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S; Christopoulos P; Yuan Z; Angeles AK; Gu L; Volckmar AL; Ogrodnik SJ; Janke F; Fratte CD; Zemojtel T; Schneider MA; Kazdal D; Endris V; Meister M; Muley T; Cecchin E; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
EBioMedicine; 2020 Dec; 62():103103. PubMed ID: 33161228
[TBL] [Abstract][Full Text] [Related]
8. Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction.
Peitz C; Sprüssel A; Linke RB; Astrahantseff K; Grimaldi M; Schmelz K; Toedling J; Schulte JH; Fischer M; Messerschmidt C; Beule D; Keilholz U; Eggert A; Deubzer HE; Lodrini M
J Mol Diagn; 2020 Nov; 22(11):1309-1323. PubMed ID: 32858250
[TBL] [Abstract][Full Text] [Related]
9. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients.
Iehara T; Yagyu S; Gotoh T; Ouchi K; Yoshida H; Miyachi M; Kikuchi K; Sugimoto T; Hosoi H
Jpn J Clin Oncol; 2019 Aug; 49(8):743-748. PubMed ID: 31053863
[TBL] [Abstract][Full Text] [Related]
10. Detection of tumor ALK status in neuroblastoma patients using peripheral blood.
Combaret V; Iacono I; Bellini A; Bréjon S; Bernard V; Marabelle A; Coze C; Pierron G; Lapouble E; Schleiermacher G; Blay JY
Cancer Med; 2015 Apr; 4(4):540-50. PubMed ID: 25653133
[TBL] [Abstract][Full Text] [Related]
11. Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.
Trivedi T; Panchal K; Bhalala N; Trivedi P; Panchal H
World Neurosurg; 2022 Mar; 159():e48-e57. PubMed ID: 34861448
[TBL] [Abstract][Full Text] [Related]
12. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
13. Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR; Giudice AM; Lane MV; McIntyre B; Schürch PM; Pascual-Pasto G; Buongervino SN; Suresh S; Fitzsimmons A; Hyman A; Gemino-Borromeo M; Saggio J; Berko ER; Daniels AA; Stundon J; Friedrichsen M; Liu X; Margolis ML; Li MM; Tierno MB; Oxnard GR; Maris JM; Mossé YP
Cancer Discov; 2022 Dec; 12(12):2800-2819. PubMed ID: 36108156
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of copy number alterations by liquid biopsy for neuroblastoma.
Shirai R; Osumi T; Sato-Otsubo A; Nakabayashi K; Ishiwata K; Yamada Y; Yoshida M; Yoshida K; Shioda Y; Kiyotani C; Terashima K; Tomizawa D; Takasugi N; Takita J; Miyazaki O; Kiyokawa N; Yoneda A; Kanamori Y; Hishiki T; Matsumoto K; Hata K; Yoshioka T; Kato M
Genes Chromosomes Cancer; 2022 Nov; 61(11):662-669. PubMed ID: 35655408
[TBL] [Abstract][Full Text] [Related]
15. Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without
Wieczorek A; Szewczyk K; Klekawka T; Stefanowicz J; Ussowicz M; Drabik G; Pawinska-Wasikowska K; Balwierz W
Front Oncol; 2023; 13():1134772. PubMed ID: 36865795
[TBL] [Abstract][Full Text] [Related]
16. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
17. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.
Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Front Oncol; 2023; 13():1176698. PubMed ID: 37333831
[TBL] [Abstract][Full Text] [Related]
18. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
19. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S; Iehara T; Tanaka S; Gotoh T; Misawa-Furihata A; Sugimoto T; London WB; Hogarty MD; Teramukai S; Nakagawara A; Hiyama E; Maris JM; Hosoi H
PLoS One; 2016; 11(8):e0161039. PubMed ID: 27513929
[TBL] [Abstract][Full Text] [Related]
20. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
